| 12.31 0.18 (1.48%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.79 | 1-year : | 17.28 |
| Resists | First : | 12.67 | Second : | 14.79 |
| Pivot price | 11.86  |
|||
| Supports | First : | 11.16 | Second : | 10.23 |
| MAs | MA(5) : | 12.32 |
MA(20) : | 11.62 |
| MA(100) : | 12.49  |
MA(250) : | 11.08 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 77.7 |
D(3) : | 83.7 |
| RSI | RSI(14): 58.9 |
|||
| 52-week | High : | 15.43 | Low : | 7.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed below upper band by 26.3%. Bollinger Bands are 5.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.4 - 12.46 | 12.46 - 12.52 |
| Low: | 11.92 - 11.98 | 11.98 - 12.04 |
| Close: | 12.21 - 12.31 | 12.31 - 12.41 |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Thu, 25 Jul 2024
Swiss National Bank Acquires 6,100 Shares of Evolus, Inc. (NASDAQ:EOLS) - Defense World
Thu, 25 Jul 2024
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference - Yahoo Finance Australia
Thu, 25 Jul 2024
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference - StockTitan
Wed, 24 Jul 2024
Evolus (EOLS) Set to Announce Earnings on Wednesday - MarketBeat
Sun, 21 Jul 2024
SG Americas Securities LLC Decreases Stock Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Sat, 20 Jul 2024
Lord Abbett & CO. LLC Makes New $11.63 Million Investment in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 63 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 81.3 (%) |
| Shares Short | 4,750 (K) |
| Shares Short P.Month | 4,450 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | -27.4 % |
| Operating Margin | -12.4 % |
| Return on Assets (ttm) | -10.7 % |
| Return on Equity (ttm) | -472.7 % |
| Qtrly Rev. Growth | 42.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.5 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -11.84 |
| PEG Ratio | -2.3 |
| Price to Book value | 41.03 |
| Price to Sales | 3.5 |
| Price to Cash Flow | -32.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|